Academic Medical Center University of Amsterdam

WALTHAM, Mass.--( BUSINESS WIRE )-- Paragonix Technologies , a leading organ transplant company, announced today the first liver transplant case in which a pediatric donor liver was preserved using the LIVERguard ® Donor Liver Preservation System and successfully transplanted by Dr. Deepak Vikraman at Duke University Hospital in Durham, NC. Launched in 2022, the Paragonix LIVERguard has now been used in over 300 clinical liver transplant cases across the United States, with this case being the first use in a pediatric setting. The LIVERguard System has been shown in recent clinical presentations to reduce potential post-transplant complications compared to traditional ice storage. 1 These presentations are recent clinical reports from the GUARDIAN-LIVER global clinical registry, a comprehensive study that seeks to evaluate a missing piece of the organ procurement process: the impact of methods and technologies used for liver preservation and transportation. Additionally, the LIVERguard system has been used by liver transplant centers across the U.S. to change the way donor livers are procured and allocated, including long distance procurements from Puerto Rico and Hawaii , and the enablement of OPOs to place high-risk donor livers. “This case exemplifies the importance of employing the latest innovations in transplant preservation within pediatric care,” said Dr. Vikraman, liver transplant surgeon at Duke. “New technologies are pushing the boundaries of what was previously possible. By advancing preservation methods, we can expand donor pools and offer young patients a second chance at life.” LIVERguard provides a highly controlled, state-of-the art environment for hypothermic liver preservation, complemented by real-time digital monitoring, to protect the donor liver throughout the entire transplant process. Unlike traditional methods using ice and off-the-shelf coolers, which have been the standard of care for over 50 years, the LIVERguard represents a significant advancement in organ transplantation technology. “We are thrilled to see our technology utilized in the pediatric setting, extending its impact to more liver transplant patients and improving preservation techniques and outcomes for children,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies. “Partnering with a leading pediatric liver transplant center like Duke University, whose mission it is to provide extraordinary care aligns perfectly with our vision of improving outcomes. It is truly exciting to work together to transform the healthcare system for the better.” For more information about Paragonix Advanced Organ Preservation devices, please visit www.paragonix.com . About Paragonix Technologies Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation. Paragonix Technologies provides Advanced Organ Preservation (“AOP”) devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com . Follow us on Twitter: @ParagonixSherpa Connect with us on LinkedIn: Paragonix Technologies Like Us on Facebook: Paragonix Technologies References Brubaker et al, ILTS 2024 Presentation.

DUBLIN, June 23, 2023 /PRNewswire/ -- The "Global Bioinformatics Partnering Terms and Agreements 2016 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Bioinformatics Partnering Terms and Agreements 2016 to 2023 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in bioinformatics partnering deals Partnering agreement structure Partnering contract documents Top deals by value Most active deal makers Financial deal terms for bioinformatics Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2016, including financial terms where available, including over 1600 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading bioinformatics deals since 2016. Deals are listed by headline value, signed by big pharma, most active bioinformatics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in bioinformatics dealmaking with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2016. The chapter is organized by specific bioinformatics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z, deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products. The report provides the reader with the following key benefits: In-depth understanding of bioinformatics deal trends since 2016 Access to headline, upfront, milestone and royalty data Comprehensive access to over 1600 bioinformatics deals entered into by the world's biopharma companies Detailed access to actual bioinformatics contracts enter into by the leading big pharma companies Insight into the terms included in a bioinformatics agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Companies Mentioned 1QBit 2bPrecise 3B Medical 3D Signatures 3D Systems 3M 4HF Biotec 10X Genomics 23andMe 111 121nexus A2A Pharmaceuticals A3 Informatics Abarca Abbott Laboratories Abbvie Abramson Cancer Center Abyde Academic Medical Center Accelerated Enrollment Solutions Accelq Accenture AccessDx Laboratory Accuray AccuWeather Acentrus Specialty Achilles Therapeutics Actigraph Active Motif ActX Acuant Acumen Analytics Acurian Adapt Analytics Adaptiiv Adaptive Biotechnologies Adaptive Research ADAS 3D Medical Adents Adhera Therapeutics AdhereHealth Aditx Therapeutics Adracare Advaita Advanced Biological Laboratories Advanced Clinical Advanced Guidance Technologies Advanced Radiation Therapy Advantech Advarra and many, many more! For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

BETHLEHEM, Pa., Aug. 15, 2022 /PRNewswire/ -- Monkeypox is an increasing worldwide problem recently declared a public health emergency in the United States. Among classical symptoms that include fever, muscle aches, lymph node swelling and rash are oral lesions present in up to 70% of cases. "This disease is not as easily transmitted as COVID 19," said Dr. Jeffrey Jahre, St. Luke's senior vice president of Medical and Academic Affairs and section chief emeritus of Infectious Diseases. "Early recognition by all healthcare providers including dentists can potentially bring the spread of this disease to a halt." Dr. Jahre said St. Luke's is calling on the dental community to be alert for monkeypox because Network doctors have begun seeing oral monkeypox symptoms. The American Dental Association has said that the standard infection control precautions used by dentists for decades, including the enhanced protocols that have been implemented during the COVID-19 pandemic, continue to keep both patients and staff safe during the monkeypox emergency. Monkeypox is transmitted most commonly through direct contact with body fluids or lesions of the body of someone who has the disease. Less commonly it can also spread through materials that have touched these skin lesions or sores. Close contact with respiratory droplet secretions may be another uncommon mode of spread though the exact frequency is unknown. "It is very important at this time that oral care programs, such those that train dental hygienists and other dental professionals, are aware of and alert to oral monkeypox symptomology and understand how to handle cases," said Dr. Wayne Saunders, DMD, Chief of St. Luke's Oral & Maxillofacial Surgery. The facial lesions can vary in number and location including lips and can be papules, pustules, clear vesicles, or open sores with or without scab formation. The intraoral lesions are equally diverse and could be present anywhere in the mouth including gums, tongue, cheeks, palate and throat. These lesions can resemble other well-known conditions such as cold sores (herpes simplex), canker sores, lesions of hand-foot-mouth disease, or trauma. A search of a Google images of monkeypox facial and oral lesions can provide a useful guide. The importance of taking into consideration patients' medical history to try and ascertain the etiology cannot be over emphasized. Currently more than 95% of the monkeypox cases involve men who have sexual relations with men who have multiple sexual partners. However, the disease is expanding beyond this group, so symptoms in others cannot be ignored. When suspicious lesions are present, the patient can be referred to primary care providers or urgent care centers for conclusive testing, advised Dr. Saunders. About St. Luke's Founded in 1872, St. Luke's University Health Network is a fully integrated, regional, non-profit network of more than 18,000 employees providing services at 14 campuses and 300+ outpatient sites. With annual net revenue of $3 billion, the Network's service area includes 11 counties in Pennsylvania and New Jersey. Dedicated to advancing medical education, St. Luke's is the preeminent teaching hospital in central-eastern Pennsylvania. SOURCE St. Luke's University Health Network